nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.12.2010 | NON-THEMATIC REVIEW

Expression of tenascin-C and its isoforms in the breast

verfasst von: David S. Guttery, Jacqueline A. Shaw, Kirsty Lloyd, J. Howard Pringle, Rosemary A. Walker

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Tenascin-C (TNC) is an extracellular matrix glycoprotein which is frequently up-regulated in a variety of pathological conditions including chronic inflammation and cancer. TNC has been implicated in the modulation of cell migration, proliferation, invasion and angiogenesis. Multiple isoforms of TNC can be generated through the alternative splicing of nine exons located in the fibronectin type III region of the molecule. The profile of isoforms expressed differs between cancers and normal breast, with the fully truncated TNC isoform being predominant in normal and benign tissues and higher molecular weight isoforms induced predominantly in cancer. The addition of extra domains within the fibronectin type III repeat domain greatly affects TNC function with multiple exon combinations available for splicing. Exons 14 and 16 are considered to be tumour-associated and have been shown to affect breast cell line invasion and growth in vitro to a greater extent than the full-length TNC isoform. This mini review will provide a summary of the literature to date regarding the expression of TNC isoforms in the breast and also discuss more recent developments in the field regarding exon AD1.

Bissell, M. J., & Radisky, D. (2001). Putting tumours in context. Nature Reviews Cancer, 1, 46–54.PubMed

Liotta, L. A., & Kohn, E. C. (2001). The microenvironment of the tumour–host interface. Nature, 411, 375–379.PubMed

de Visser, K. E., & Coussens, L. M. (2006). The inflammatory tumor microenvironment and its impact on cancer development. Contributions to Microbiology, 13, 118–137.PubMed

Egeblad, M., Littlepage, L. E., & Werb, Z. (2005). The fibroblastic coconspirator in cancer progression. Cold Spring Harbor Symposia on Quantative Biology, 70, 383–388.

Ma, X. J., Dahiya, S., Richardson, E., Erlander, M., & Sgroi, D. C. (2009). Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Research, 11, R7.PubMed

Kalluri, R., & Zeisberg, M. (2006). Fibroblasts in cancer. Nature Reviews Cancer, 6, 392–401.PubMed

Carnemolla, B., Castellani, P., Ponassi, M., Borsi, L., Urbini, S., Nicolo, G., et al. (1999). Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. American Journal of Pathology, 154, 1345–1352.PubMed

Fuss, B., Pott, U., Fischer, P., Schwab, M. E., & Schachner, M. (1991). Identification of a cDNA clone specific for the oligodendrocyte-derived repulsive extracellular matrix molecule J1-160/180. Journal of Neuroscience Research, 29, 299–307.PubMed

Weber, P., Montag, D., Schachner, M., & Bernhardt, R. R. (1998). Zebrafish tenascin-W, a new member of the tenascin family. Journal of Neurobiology, 35, 1–16.PubMed

10.

Scherberich, A., Tucker, R. P., Degen, M., Brown-Luedi, M., Andres, A. C., & Chiquet-Ehrismann, R. (2005). Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro. Oncogene, 24, 1525–1532.PubMed

11.

Degen, M., Brellier, F., Kain, R., Ruiz, C., Terracciano, L., Orend, G., et al. (2007). Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior. Cancer Research, 67, 9169–9179.PubMed

12.

Bristow, J., Tee, M. K., Gitelman, S. E., Mellon, S. H., & Miller, W. L. (1993). Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B. Journal of Cell Biology, 122, 265–278.PubMed

13.

Mao, J. R., Taylor, G., Dean, W. B., Wagner, D. R., Afzal, V., Lotz, J. C., et al. (2002). Tenascin-X deficiency mimics Ehlers–Danlos syndrome in mice through alteration of collagen deposition. Nature Genetics, 30, 421–425.PubMed

14.

Burch, G. H., Gong, Y., Liu, W., Dettman, R. W., Curry, C. J., Smith, L., et al. (1997). Tenascin-X deficiency is associated with Ehlers–Danlos syndrome. Nature Genetics, 17, 104–108.PubMed

15.

Hagios, C., Koch, M., Spring, J., Chiquet, M., & Chiquet-Ehrismann, R. (1996). Tenascin-Y: A protein of novel domain structure is secreted by differentiated fibroblasts of muscle connective tissue. Journal of Cell Biology, 134, 1499–1512.PubMed

16.

Chiquet-Ehrismann, R. (2004). Tenascins. International Journal of Biochemistry & Cell Biology, 36, 986–990.

17.

Chiquet-Ehrismann, R., & Chiquet, M. (2003). Tenascins: Regulation and putative functions during pathological stress. Journal of Pathology, 200, 488–499.PubMed

18.

Hsia, H. C., & Schwarzbauer, J. E. (2005). Meet the tenascins: Multifunctional and mysterious. Journal of Biological Chemistry, 280, 26641–26644.PubMed

19.

Chung, C. Y., Murphy-Ullrich, J. E., & Erickson, H. P. (1996). Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Molecular Biology of the Cell, 7, 883–892.PubMed

20.

Ghert, M. A., Qi, W. N., Erickson, H. P., Block, J. A., & Scully, S. P. (2001). Tenascin-C splice variant adhesive/anti-adhesive effects on chondrosarcoma cell attachment to fibronectin. Cell Structure and Function, 26, 179–187.PubMed

21.

Midwood, K. S., & Orend, G. (2009). The role of tenascin-C in tissue injury and tumorigenesis. Journal of Cell Communication and Signaling, 3, 287–310.PubMed

22.

Jones, P. L., & Jones, F. S. (2000). Tenascin-C in development and disease: Gene regulation and cell function. Matrix Biology, 19, 581–596.PubMed

23.

Jones, F. S., & Jones, P. L. (2000). The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling. Developmental Dynamics, 218, 235–259.PubMed

24.

Erickson, H. P., & Inglesias, J. L. (1984). A six-armed oligomer isolated from cell surface fibronectin preparations. Nature, 311, 267–269.PubMed

25.

Hancox, R. A., Allen, M. D., Holliday, D. L., Edwards, D. R., Pennington, C. J., Guttery, D. S., et al. (2009). Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Research, 11, R24.PubMed

26.

Orend, G., & Chiquet-Ehrismann, R. (2006). Tenascin-C induced signaling in cancer. Cancer Letters, 244, 143–163.PubMed

27.

Howeedy, A. A., Virtanen, I., Laitinen, L., Gould, N. S., Koukoulis, G. K., & Gould, V. E. (1990). Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Laboratory Investigation, 63, 798–806.PubMed

28.

Jahkola, T., Toivonen, T., Virtanen, I., von Smitten, K., Nordling, S., von Boguslawski, K., et al. (1998). Tenascin-C expression in invasion border of early breast cancer: A predictor of local and distant recurrence. British Journal of Cancer, 78, 1507–1513.PubMed

29.

Adams, M., Jones, J. L., Walker, R. A., Pringle, J. H., & Bell, S. C. (2002). Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Research, 62, 3289–3297.PubMed

30.

Murphy-Ullrich, J. E., Lightner, V. A., Aukhil, I., Yan, Y. Z., Erickson, H. P., & Hook, M. (1991). Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. Journal of Cell Biology, 115, 1127–1136.PubMed

31.

Phillips, G. R., Krushel, L. A., & Crossin, K. L. (1998). Domains of tenascin involved in glioma migration. Journal of Cell Science, 111(Pt 8), 1095–1104.PubMed

32.

Taraseviciute, A., Vincent, B. T., Schedin, P., & Jones, P. L. (2010). Quantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function. American Journal of Pathology, 176, 827–838.PubMed

33.

Chiquet-Ehrismann, R., Mackie, E. J., Pearson, C. A., & Sakakura, T. (1986). Tenascin: An extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell, 47, 131–139.PubMed

34.

Russo, J., & Russo, I. H. (1996). Experimentally induced mammary tumors in rats. Breast Cancer Research and Treatment, 39, 7–20.PubMed

35.

Tsubura, A., Yoshizawa, K., Uehara, N., Yuri, T., & Matsuoka, Y. (2007). Multistep mouse mammary tumorigenesis through pre-neoplasia to neoplasia and acquisition of metastatic potential. Medical Molecular Morphology, 40, 9–17.PubMed

36.

Mackie, E. J., Chiquet-Ehrismann, R., Adams Pearson, C., Inaguma, Y., Taya, K., Kawarada, Y., et al. (1987). Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proceedings of the National Academy of Sciences U S A, 84, 4621–4625.

37.

Inaguma, Y., Kusakabe, M., Mackie, E. J., Pearson, C. A., Chiquet-Ehrismann, R., & Sakakura, T. (1988). Epithelial induction of stromal tenascin in the mouse mammary gland: From embryogenesis to carcinogenesis. Developmental Biology, 128, 245–255.PubMed

38.

Bell, S. C., Pringle, J. H., Taylor, D. J., & Malak, T. M. (1999). Alternatively spliced tenascin-C mRNA isoforms in human fetal membranes. Molecular Human Reproduction, 5, 1066–1076.PubMed

39.

Erickson, H. P., & Bourdon, M. A. (1989). Tenascin: An extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annual Review of Cell Biology, 5, 71–92.PubMed

40.

Erickson, H. P., & Lightner, V. A. (1988). Hexabrachion protein (tenascin, cytotactin, brachionectin) in connective tissues, embryonic brain, and tumors. Advanced Cell Biology, 2, 55–90.

41.

Chiquet-Ehrismann, R., Kalla, P., & Pearson, C. A. (1989). Participation of tenascin and transforming growth factor-beta in reciprocal epithelial–mesenchymal interactions of MCF7 cells and fibroblasts. Cancer Research, 49, 4322–4325.PubMed

42.

Maschler, S., Grunert, S., Danielopol, A., Beug, H., & Wirl, G. (2004). Enhanced tenascin-C expression and matrix deposition during Ras/TGF-beta-induced progression of mammary tumor cells. Oncogene, 23, 3622–3633.PubMed

43.

Kawakatsu, H., Shiurba, R., Obara, M., Hiraiwa, H., Kusakabe, M., & Sakakura, T. (1992). Human carcinoma cells synthesize and secrete tenascin in vitro. Japanese Journal of Cancer Research, 83, 1073–1080.PubMed

44.

Lightner, V. A., Marks, J. R., & McCachren, S. S. (1994). Epithelial cells are an important source of tenascin in normal and malignant human breast tissue. Experimental Cell Research, 210, 177–184.PubMed

45.

Dandachi, N., Hauser-Kronberger, C., More, E., Wiesener, B., Hacker, G. W., Dietze, O., et al. (2001). Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: Correlation with histopathological parameters, hormone receptors, and oncoproteins. Journal of Pathology, 193, 181–189.PubMed

46.

Gordon, L. A., Mulligan, K. T., Maxwell-Jones, H., Adams, M., Walker, R. A., & Jones, J. L. (2003). Breast cell invasive potential relates to the myoepithelial phenotype. International Journal of Cancer, 106, 8–16.

47.

Jahkola, T., Toivonen, T., von Smitten, K., Blomqvist, C., & Virtanen, I. (1996). Expression of Tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. International Journal of Cancer, 69, 445–447.

48.

Jahkola, T. (1998). Self-perceptions of women after early breast cancer surgery. European Journal of Surgical Oncology, 24, 9–14.PubMed

49.

Shoji, T., Kamiya, T., Tsubura, A., Hatano, T., Sakakura, T., Yamamoto, M., et al. (1992). Immunohistochemical staining patterns of tenascin in invasive breast carcinomas. Virchows Archiv. A, Pathological Anatomy and Histopathology, 421, 53–56.PubMed

50.

Ferguson, J. E., Schor, A. M., Howell, A., & Ferguson, M. W. (1990). Tenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma. Differentiation, 42, 199–207.PubMed

51.

Vollmer, G., Siegal, G. P., Chiquet-Ehrismann, R., Lightner, V. A., Arnholdt, H., & Knuppen, R. (1990). Tenascin expression in the human endometrium and in endometrial adenocarcinomas. Laboratory Investigation, 62, 725–730.PubMed

52.

Jahkola, T., Toivonen, T., Nordling, S., von Smitten, K., & Virtanen, I. (1998). Expression of tenascin-C in intraductal carcinoma of human breast: Relationship to invasion. European Journal of Cancer, 34, 1687–1692.PubMed

53.

Goepel, C., Buchmann, J., Schultka, R., & Koelbl, H. (2000). Tenascin-A marker for the malignant potential of preinvasive breast cancers. Gynecologic Oncology, 79, 372–378.PubMed

54.

Tokes, A. M., Paku, S., Toth, S., Paal, E., Kulka, J., Toth, J., et al. (2000). Tenascin expression in primary and recurrent breast carcinomas and the effect of tenascin on breast tumor cell cultures. Pathology and Oncology Research, 6, 202–209.PubMed

55.

Gould, V. E., Koukoulis, G. K., & Virtanen, I. (1990). Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast. Cell Differentiation and Development, 32, 409–416.PubMed

56.

Koukoulis, G. K., Gould, V. E., Bhattacharyya, A., Gould, J. E., Howeedy, A. A., & Virtanen, I. (1991). Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: Biologic and pathologic implications. Human Pathology, 22, 636–643.PubMed

57.

Moch, H., Torhorst, J., Durmuller, U., Feichter, G. E., Sauter, G., & Gudat, F. (1993). Comparative analysis of the expression of tenascin and established prognostic factors in human breast cancer. Pathology, Research and Practice, 189, 510–514.PubMed

58.

Natali, P. G., Nicotra, M. R., Bigotti, A., Botti, C., Castellani, P., Risso, A. M., et al. (1991). Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. International Journal of Cancer, 47, 811–816.

59.

Shrestha, P., Sakamoto, F., Takagi, H., Yamada, T., & Mori, M. (1994). Enhanced tenascin immunoreactivity in leukoplakia and squamous cell carcinoma of the oral cavity: An immunohistochemical study. European Journal of Cancer Part B: Oral Oncology, 30B, 132–137.

60.

Shrestha, P., Sumitomo, S., Ogata, K., Yamada, K., Takai, Y., Yang, L., et al. (1994). Immunoreactive tenascin in tumours of salivary glands: Evidence for enhanced expression in tumour stroma and production by tumour cells. European Journal of Cancer Part B: Oral Oncology, 30B, 393–399.

61.

Yamanaka, M., Taga, M., & Minaguchi, H. (1996). Immunohistological localization of tenascin in the human endometrium. Gynecologic and Obstetric Investigation, 41, 247–252.PubMed

62.

Weigelt, B., Peterse, J. L., & van’t Veer, L. J. (2005). Breast cancer metastasis: Markers and models. Nature Reviews Cancer, 5, 591–602.PubMed

63.

Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nature Reviews Cancer, 9, 239–252.PubMed

64.

Tsunoda, T., Inada, H., Kalembeyi, I., Imanaka-Yoshida, K., Sakakibara, M., Okada, R., et al. (2003). Involvement of large tenascin-C splice variants in breast cancer progression. American Journal of Pathology, 162, 1857–1867.PubMed

65.

Emoto, K., Yamada, Y., Sawada, H., Fujimoto, H., Ueno, M., Takayama, T., et al. (2001). Annexin II overexpression correlates with stromal tenascin-C overexpression: A prognostic marker in colorectal carcinoma. Cancer, 92, 1419–1426.PubMed

66.

Kusagawa, H., Onoda, K., Namikawa, S., Yada, I., Okada, A., Yoshida, T., et al. (1998). Expression and degeneration of tenascin-C in human lung cancers. British Journal of Cancer, 77, 98–102.PubMed

67.

Leins, A., Riva, P., Lindstedt, R., Davidoff, M. S., Mehraein, P., & Weis, S. (2003). Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer, 98, 2430–2439.PubMed

68.

Ioachim, E., Charchanti, A., Briasoulis, E., Karavasilis, V., Tsanou, H., Arvanitis, D. L., et al. (2002). Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: Their prognostic value and role in tumour invasion and progression. European Journal of Cancer, 38, 2362–2370.PubMed

69.

Thiery, J. P. (2002). Epithelial–mesenchymal transitions in tumour progression. Nature Reviews Cancer, 2, 442–454.PubMed

70.

Tavazoie, S. F., Alarcón, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P. D., et al. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451, 147–152.PubMed

71.

Sugawara, I., Hirakoshi, J., Masunaga, A., Itoyama, S., & Sakakura, T. (1991). Reduced tenascin expression in colonic carcinoma with lymphogenous metastasis. Invasion and Metastasis, 11, 325–331.

72.

Shoji, T., Kamiya, T., Tsubura, A., Hamada, Y., Hatano, T., Hioki, K., et al. (1993). Tenascin staining positivity and the survival of patients with invasive breast carcinoma. Journal of Surgical Research, 55, 295–297.PubMed

73.

Ishihara, A., Yoshida, T., Tamaki, H., & Sakakura, T. (1995). Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clinical Cancer Research, 1, 1035–1041.PubMed

74.

Tiitta, O., Wahlstrom, T., Paavonen, J., Linnala, A., Sharma, S., Gould, V. E., et al. (1992). Enhanced tenascin expression in cervical and vulvar koilocytotic lesions. American Journal of Pathology, 141, 907–913.PubMed

75.

Helleman, J., Jansen, M. P., Ruigrok-Ritstier, K., van Staveren, I. L., Look, M. P., Meijer-van Gelder, M. E., et al. (2008). Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clinical Cancer Research, 14, 5555–5564.PubMed

76.

Joester, A., & Faissner, A. (1999). Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system. Journal of Biological Chemistry, 274, 17144–17151.PubMed

77.

von Holst, A., Egbers, U., Prochiantz, A., & Faissner, A. (2007). Neural stem/progenitor cells express 20 tenascin C isoforms that are differentially regulated by Pax6. Journal of Biological Chemistry, 282, 9172–9181.

78.

Dorries, U., & Schachner, M. (1994). Tenascin mRNA isoforms in the developing mouse brain. Journal of Neuroscience Research, 37, 336–347.PubMed

79.

Chiquet-Ehrismann, R., Matsuoka, Y., Hofer, U., Spring, J., Bernasconi, C., & Chiquet, M. (1991). Tenascin variants: Differential binding to fibronectin and distinct distribution in cell cultures and tissues. Cell Regulation, 2, 927–938.PubMed

80.

Kaplony, A., Zimmermann, D. R., Fischer, R. W., Imhof, B. A., Odermatt, B. F., Winterhalter, K. H., et al. (1991). Tenascin Mr 220000 isoform expression correlates with corneal cell migration. Development, 112, 605–614.PubMed

81.

Prieto, A. L., Jones, F. S., Cunningham, B. A., Crossin, K. L., & Edelman, G. M. (1990). Localization during development of alternatively spliced forms of cytotactin mRNA by in situ hybridization. Journal of Cell Biology, 111, 685–698.PubMed

82.

Tucker, R. P. (1991). The sequential expression of tenascin mRNA in epithelium and mesenchyme during feather morphogenesis. Roux’s Archives of Developmental Biology, 200, 108–112.

83.

Weller, A., Beck, S., & Ekblom, P. (1991). Amino acid sequence of mouse tenascin and differential expression of two tenascin isoforms during embryogenesis. Journal of Cell Biology, 112, 355–362.PubMed

84.

Joester, A., & Faissner, A. (2001). The structure and function of tenascins in the nervous system. Matrix Biology, 20, 13–22.PubMed

85.

Borsi, L., Balza, E., Castellani, P., Carnemolla, B., Ponassi, M., Querze, G., et al. (1994). Cell-cycle dependent alternative splicing of the tenascin primary transcript. Cell Adhesion and Communication, 1, 307–317.PubMed

86.

Borsi, L., Allemanni, G., Gaggero, B., & Zardi, L. (1996). Extracellular pH controls pre-mRNA alternative splicing of tenascin-C in normal, but not in malignantly transformed, cells. International Journal of Cancer, 66, 632–635.

87.

Vollmer, G., Tan, M. I., Wunsche, W., & Frank, K. (1997). Expression of tenascin-C by human endometrial adenocarcinoma and stroma cells: Heterogeneity of splice variants and induction by TGF-beta. Biochemistry and Cell Biology, 75, 759–769.PubMed

88.

Chung, C. Y., & Erickson, H. P. (1994). Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. Journal of Cell Biology, 126, 539–548.PubMed

89.

Huang, W., Chiquet-Ehrismann, R., Moyano, J. V., Garcia-Pardo, A., & Orend, G. (2001). Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Research, 61, 8586–8594.PubMed

90.

Lange, K., Kammerer, M., Saupe, F., Hegi, M. E., Grotegut, S., Fluri, E., et al. (2008). Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Research, 68, 6942–6952.PubMed

91.

Orend, G., Huang, W., Olayioye, M. A., Hynes, N. E., & Chiquet-Ehrismann, R. (2003). Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4. Oncogene, 22, 3917–3926.PubMed

92.

Ruiz, C., Huang, W., Hegi, M. E., Lange, K., Hamou, M. F., Fluri, E., et al. (2004). Growth promoting signaling by tenascin-C [corrected]. Cancer Research, 64, 7377–7385.PubMed

93.

Crossin, K. L. (1996). Tenascin: A multifunctional extracellular matrix protein with a restricted distribution in development and disease. Journal of Cellular Biochemistry, 61, 592–598.PubMed

94.

Prieto, A. L., Andersson-Fisone, C., & Crossin, K. L. (1992). Characterization of multiple adhesive and counteradhesive domains in the extracellular matrix protein cytotactin. Journal of Cell Biology, 119, 663–678.PubMed

95.

Sriramarao, P., Mendler, M., & Bourdon, M. A. (1993). Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. Journal of Cell Science, 105(Pt 4), 1001–1012.PubMed

96.

Fischer, D., Tucker, R. P., Chiquet-Ehrismann, R., & Adams, J. C. (1997). Cell-adhesive responses to tenascin-C splice variants involve formation of fascin microspikes. Molecular Biology of the Cell, 8, 2055–2075.PubMed

97.

Gotz, M., Bolz, J., Joester, A., & Faissner, A. (1997). Tenascin-C synthesis and influence on axonal growth during rat cortical development. European Journal of Neuroscience, 9, 496–506.PubMed

98.

Hauzenberger, D., Olivier, P., Gundersen, D., & Ruegg, C. (1999). Tenascin-C inhibits beta1 integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1–5 repeats to fibronectin. European Journal of Immunology, 29, 1435–1447.PubMed

99.

Julian, J., Chiquet-Ehrismann, R., Erickson, H. P., & Carson, D. D. (1994). Tenascin is induced at implantation sites in the mouse uterus and interferes with epithelial cell adhesion. Development, 120, 661–671.PubMed

100.

Krushel, L. A., Prieto, A. L., Edelman, G. M., & Crossin, K. L. (1994). Differential effects of cytotactin tenascin fusion proteins on intracellular pH and cell morphology. Journal of Cellular Physiology, 161, 508–518.PubMed

101.

Spring, J., Beck, K., & Chiquet-Ehrismann, R. (1989). Two contrary functions of tenascin: Dissection of the active sites by recombinant tenascin fragments. Cell, 59, 325–334.PubMed

102.

Borsi, L., Carnemolla, B., Nicolo, G., Spina, B., Tanara, G., & Zardi, L. (1992). Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. International Journal of Cancer, 52, 688–692.

103.

Richter, P. T. M., Franz, M., Altendorf-Hofmann, A., Junker, K., Borsi, L., Neri, D., et al. (2009). B and C domain containing tenascin-C: Urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? Journal of Cancer Research and Clinical Oncology, 135, 1351–1358.PubMed

104.

Berndt, A., Anger, K., Richter, P., Borsi, L., Brack, S., Silacci, M., et al. (2006). Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder. Journal of Cancer Research and Clinical Oncology, 132, 537–546.PubMed

105.

Herold-Mende, C., Mueller, M. M., Bonsanto, M. M., Schmitt, H. P., Kunze, S., & Steiner, H. H. (2002). Clinical impact and functional aspects of tenascin-C expression during glioma progression. International Journal of Cancer, 98, 362–369.

106.

Gazzaniga, P., Nofroni, I., Gandini, O., Silvestri, I., Frati, L., Agliano, A. M., et al. (2005). Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer. Oncology Reports, 14, 1199–1202.PubMed

107.

Parekh, K., Ramachandran, S., Cooper, J., Bigner, D., Patterson, A., & Mohanakumar, T. (2005). Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. Lung Cancer, 47, 17–29.PubMed

108.

Sis, B., Tuna, B., Yorukoglu, K., & Kargi, A. (2004). Tenascin C and cathepsin d expression in adipocytic tumors: an immunohistochemical investigation of 43 cases. International Journal of Surgical Pathology, 12, 11–15.PubMed

109.

Vacca, A., Ribatti, D., Fanelli, M., Costantino, F., Nico, B., Di Stefano, R., et al. (1996). Expression of tenascin is related to histologic malignancy and angiogenesis in b-cell non-Hodgkin’s lymphomas. Leukemia and Lymphoma, 22, 473–481.PubMed

110.

Pilch, H., Schaffer, U., Schlenger, K., Lautz, A., Tanner, B., Hockel, M., et al. (1999). Expression of tenascin in human cervical cancer-association of tenascin expression with clinicopathological parameters. Gynecologic Oncology, 73, 415–421.PubMed

111.

Iskaros, B. E., Sison, C. P., & Hajdu, S. I. (2000). Tenascin patterns of expression in duct carcinoma in situ of the breast. Annals of Clinical and Laboratory Science, 30, 266–271.PubMed

112.

Wilson, K. E., Langdon, S. P., Lessells, A. M., & Miller, W. R. (1996). Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. British Journal of Cancer, 74, 999–1004.PubMed

113.

Meiners, S., Nur-e-Kamal, M. S., & Mercado, M. L. (2001). Identification of a neurite outgrowth-promoting motif within the alternatively spliced region of human tenascin-C. Journal of Neuroscience, 21, 7215–7225.PubMed

114.

Mercado, M. L., Nur-e-Kamal, A., Liu, H. Y., Gross, S. R., Movahed, R., & Meiners, S. (2004). Neurite outgrowth by the alternatively spliced region of human tenascin-C is mediated by neuronal alpha7beta1 integrin. Journal of Neuroscience, 24, 238–247.PubMed

115.

Rigato, F., Garwood, J., Calco, V., Heck, N., Faivre-Sarrailh, C., & Faissner, A. (2002). Tenascin-C promotes neurite outgrowth of embryonic hippocampal neurons through the alternatively spliced fibronectin type III BD domains via activation of the cell adhesion molecule F3/contactin. Journal of Neuroscience, 22, 6596–6609.PubMed

116.

Cai, M., Onoda, K., Takao, M., Kyoko, I. Y., Shimpo, H., Yoshida, T., et al. (2002). Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clinical Cancer Research, 8, 1152–1156.PubMed

117.

Saito, Y., Imazeki, H., Miura, S., Yoshimura, T., Okutsu, H., Harada, Y., et al. (2007). A peptide derived from tenascin-C induces beta1 integrin activation through syndecan-4. Journal of Biological Chemistry, 282, 34929–34937.PubMed

118.

Siri, A., Knauper, V., Veirana, N., Caocci, F., Murphy, G., & Zardi, L. (1995). Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. Journal of Biological Chemistry, 270, 8650–8654.PubMed

119.

Martin, D., Brown-Luedi, M., & Chiquet-Ehrismann, R. (2003). Tenascin-C signaling through induction of 14-3-3 tau. Journal of Cell Biology, 160, 171–175.PubMed

120.

Sriramarao, P., & Bourdon, M. A. (1993). A novel tenascin type III repeat is part of a complex of tenascin mRNA alternative splices. Nucleic Acids Research, 21, 163–168.PubMed

121.

Derr, L. B., Chiquet-Ehrismann, R., Gandour-Edwards, R., Spence, J., & Tucker, R. P. (1997). The expression of tenascin-C with the AD1 variable repeat in embryonic tissues, cell lines and tumors in various vertebrate species. Differentiation, 62, 71–82.PubMed

122.

Tucker, R. P. (1998). Quantitative in situ localization of tenascin-C alternatively spliced transcripts in the avian optic tectum. Molecular Vision, 4, 18.PubMed

123.

Guttery, D. S., Hancox, R. A., Mulligan, K. T., Hughes, S., Lambe, S. M., Pringle, J. H., et al. (2010). Association of invasion-promoting tenascin-C additional domains with breast cancer in young women. Breast Cancer Research, 12(4), R57.

Titel: Expression of tenascin-C and its isoforms in the breast
verfasst von: David S. Guttery
Jacqueline A. Shaw
Kirsty Lloyd
J. Howard Pringle
Rosemary A. Walker
Publikationsdatum: 01.12.2010
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 4/2010
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9249-9

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Expression of tenascin-C and its isoforms in the breast

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability

The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network

Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis

Distant metastases do not metastasize

DNA repair pathways and their implication in cancer treatment

Stem cell marker olfactomedin 4: critical appraisal of its characteristics and role in tumorigenesis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie